Combination treatment of advanced pancreatic cancer using novel vaccine and traditional therapies

References

• Sener SF, Fremgen A, Menck HR, et al.: Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 189:1–7, 1999
   Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–1825.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–1703.
   PubMed Web of Science ®Google Scholar
• Panda A, Betigeri A, Subramanian K, et al., Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors. JCO Precision Oncology. 1-13. 2017.
   Google Scholar
• Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Molecular Cancer Therapeutics:Molcanther. . 2017;0386; 2598-2608.
   Google Scholar
• Mallinson C, Rake M, Cocking J, et al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. Br Med J. 1980;281:1589–1591.
   PubMedGoogle Scholar
• Thomas AM, Santarsiero LM, Lutz ER, et al. Mesothelin-specific CD8+ T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. Journal of Experimental Medicine. 2004;200:297–306.
   PubMed Web of Science ®Google Scholar
• Berd D, Maguire HC. Mastrangelo MJ: induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Research. 1986;46:2572–2577.
   PubMed Web of Science ®Google Scholar
• Ercolini AM, Ladle BH, Manning EA, et al. Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response. Journal of Experimental Medicine. 2005;201:1591–1602.
   PubMed Web of Science ®Google Scholar
• Heinemann V, Hertel LW, Grindey GB, et al. Comparison of the cellular pharmacokinetics and toxicity of 2′, 2′-difluorodeoxycytidine and 1-β-d-arabinofuranosylcytosine. Cancer Res. 1988;48:4024–4031.
   PubMed Web of Science ®Google Scholar
• Huang P, Chubb S, Hertel LW, et al. Action of 2′, 2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991;51:6110–6117.
   PubMed Web of Science ®Google Scholar
• Gandhi V. Plunkett W: modulatory activity of 2′, 2′-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res. 1990;50:3675–3680.
   PubMed Web of Science ®Google Scholar
• Burris. 3rd H, Moore MJ, Andersen J, et al: improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology. 1997;15:2403–2413.
   PubMed Web of Science ®Google Scholar
• Kan S, Hazama S, Maeda K, et al. Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro. Anticancer Res. 2012;32:5363–5369.
   PubMed Web of Science ®Google Scholar
• Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anti-Cancer Drugs. 1996;7:548–557.
   PubMed Web of Science ®Google Scholar
• El Sayed YM. Sadée W: metabolic activation of ftorafur [R, S-1-(tetrahydro-2-furanyl)-5-fluorouracil]: the microsomal oxidative pathway. Biochemical Pharmacology. 1982;31:3006-3008.
   Web of Science ®Google Scholar
• Hirose T, Fujita K-I, Nishimura K, et al. Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer. Oncology Reports. 2010;24:529–536.
   PubMed Web of Science ®Google Scholar
• Okusaka T, Funakoshi A, Furuse J, et al. A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2008;61:615–621.
   PubMed Web of Science ®Google Scholar
• Ahmed SU, Okamoto M, Oshikawa T, et al. Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of toll-like receptor 4. Journal of Immunotherapy. 2004;27:432–441.
   PubMed Web of Science ®Google Scholar
• Kimura Y, Tsukada J, Tomoda T, et al. Clinical and immunologic evaluation of dendritic cell–based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. Pancreas. 2012;41:195–205.
   PubMed Web of Science ®Google Scholar
• Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. European Journal of Cancer. 1998;34:1274–1281.
   PubMed Web of Science ®Google Scholar
• Schüller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45:291–297.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Journal of Clinical Oncology. 2009;27:5513–5518.
   PubMed Web of Science ®Google Scholar
• Middleton G, Greenhalf W, Costello E, et al. Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma. Br J Cancer. 2016;114:510-518.
   Web of Science ®Google Scholar
• Ueno H, Okusaka T, Funakoshi A, et al. A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2007;59:447–454.
   PubMed Web of Science ®Google Scholar
• Wagener DT, Verdonk H, Dirix L, et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol. 1995;6:129–132.
   PubMed Web of Science ®Google Scholar
• Azrak RG, Cao S, Slocum HK, et al. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clinical Cancer Research. 2004;10:1121–1129.
   PubMed Web of Science ®Google Scholar
• Mans DRA, Grivicich I, Peters GJ, et al. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan–5-fluorouracil combination in human colon carcinoma cell lines. European Journal of Cancer. 1999;35:1851-1861.
   Web of Science ®Google Scholar
• Mullany S, Svingen PA, Kaufmann SH, et al. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity. Cancer Chemother Pharmacol. 1998;42:391–399.
   PubMed Web of Science ®Google Scholar
• Pavillard V, Formento P, Rostagno P, et al. Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity. Biochemical Pharmacology. 1998;56:1315–1322.
   PubMed Web of Science ®Google Scholar
• Ducreux M, Mitry E, Ould-Kaci M, et al. Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Annals of Oncology. 2004;15:467–473.
   PubMed Web of Science ®Google Scholar
• Duffy A. Greten T: immunological off-target effects of standard treatments in gastrointestinal cancers. Annals of Oncology. 2013;25:24–32.
   PubMed Web of Science ®Google Scholar
• Frese KK, Neesse A, Cook N, et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. In Cancer discovery. 2012;  March ; 2(3): 260–269.
   Google Scholar
• Cullis JE, Siolas D, Avanzi A, et al. Macropinocytosis of nab-paclitaxel drives macrophage activation in pancreatic cancer. Cancer Immunology Research:Canimm.. 2017;0125.2016.182-190.
   Google Scholar
• Siolas D, Cullis J, Avanzi A, et al. Antitumor activity and immune reponse in CD40 immunotherapy with gemcitabine and nab-paclitaxel in an orthotopic pancreatic cancer mouse model. J Clin Oncol. 2016;34:271.
   Google Scholar
• Moertel C, Frytak S, Hahn R, et al. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+ 5‐fluorouracil), and high dose radiation+ 5‐fluorouracil. The Gastrointestinal Tumor Study Group. Cancer. 1705-1710;48:1981.
   Google Scholar
• Shibuya K, Oya N, Fujii T, et al. Phase II study of radiation therapy combined with weekly low-dose gemcitabine for locally advanced, unresectable pancreatic cancer. American Journal of Clinical Oncology. 2011;34:115–119.
   PubMed Web of Science ®Google Scholar
• Shinchi H, Takao S, Noma H, et al. Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. International Journal of Radiation Oncology• Biology• Physics. 2002;53:146–150.
   PubMed Web of Science ®Google Scholar
• Ehlers G. Fridman M: abscopal effect of radiation in papillary adenocarcinoma. The British Journal of Radiology. 1973;46:220–222.
   PubMed Web of Science ®Google Scholar
• Lugade AA, Moran JP, Gerber SA, et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005;174:7516–7523.
   PubMed Web of Science ®Google Scholar
• Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114:589–595.
   PubMed Web of Science ®Google Scholar
• Cao ZA, Daniel D. Hanahan D: sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer. BMC Cancer. 2002;2:11.
   Web of Science ®Google Scholar
• Crittenden M, Kohrt H, Levy R, et al. Current clinical trials testing combinations of immunotherapy and radiation, Seminars in radiation. Oncology, Elsevier. 2015;Vol. 25, No. 1, 54–64.
   Google Scholar
• Rosenberg S. The development of new cancer therapies based on the molecular identification of cancer regression antigens. The Cancer Journal from Scientific American. 1995;1:90–100.
   PubMedGoogle Scholar
• Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Medicine. 1998;4:321–327.
   PubMed Web of Science ®Google Scholar
• Slingluff Jr CL. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?. Cancer J. 2011;17:343-350.
   Web of Science ®Google Scholar
• Yan H-X, Cheng P, Wei H-Y, et al. Active immunotherapy for mouse breast cancer with irradiated whole-cell vaccine expressing VEGFR2. Oncology Reports. 2013;29:1510–1516.
   PubMed Web of Science ®Google Scholar
• Steinman RM. The dendritic cell system and its role in immunogenicity. Annual Review of Immunology. 1991;9:271–296.
   PubMed Web of Science ®Google Scholar
• Palucka K. Banchereau J: dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013;39:38–48.
   PubMed Web of Science ®Google Scholar
• Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem. 1990;265:15286–15293.
   PubMed Web of Science ®Google Scholar
• Sahraei M, Roy LD, Curry JM, et al. MUC1 regulates PDGFA expression during pancreatic cancer progression. Oncogene. 2012;31:4935-4945.
   Web of Science ®Google Scholar
• Chaika NV, Gebregiworgis T, Lewallen ME, et al.: MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Proceedings of the National Academy of Sciences 109:13787–13792, 2012.
   Google Scholar
• Lüttges J, Feyerabend B, Buchelt T, et al. The mucin profile of noninvasive and invasive mucinous cystic neoplasms of the pancreas. The American Journal of Surgical Pathology. 2002;26:466–471.
   PubMed Web of Science ®Google Scholar
• Masaki Y, Oka M, Ogura Y, et al. Sialylated MUC1 mucin expression in normal pancreas, benign pancreatic lesions, and pancreatic ductal adenocarcinoma. Hepato-gastroenterology. 1999;46:2240–2245.
   PubMedGoogle Scholar
• Kawaoka T, Oka M, Takashima M, et al. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1. Oncology Reports. 2008;20:155–163.
   PubMed Web of Science ®Google Scholar
• Shindo Y, Hazama S, Maeda Y, et al. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer. Journal of Translational Medicine. 2014;12:175.
   Web of Science ®Google Scholar
• Matsui H, Hazama S, Sakamoto K, et al. Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy. Pancreas. 2017;46:994-1002.
   Web of Science ®Google Scholar
• Chang K, Pastan I: molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proceedings of the National Academy of Sciences 93:136–140, 1996.
   Google Scholar
• Chang K, Pastan I. Willingham MC: isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. International Journal of Cancer. 1992;50:373–381.
   PubMed Web of Science ®Google Scholar
• Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clinical Cancer Research. 2001;7:3862–3868.
   PubMed Web of Science ®Google Scholar
• Rump A, Morikawa Y, Tanaka M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004;279:9190–9198.
   PubMed Web of Science ®Google Scholar
• Yamashita Y, Yokoyama M, Kobayashi E, et al. Mapping and determination of the cDNA sequence of the Erc gene preferentially expressed in renal cell carcinoma in the Tsc2 gene mutant (Eker) rat model. Biochem Biophys Res Commun. 2000;275:134–140.
   PubMed Web of Science ®Google Scholar
• Mak BC, Takemaru K-I, Kenerson HL, et al. The tuberin-hamartin complex negatively regulates beta-catenin signaling activity.. The Journal of Biological Chemistry. 2003;278:5947–5951.
   PubMed Web of Science ®Google Scholar
• Prieve MG. Moon RT: stromelysin-1 and mesothelin are differentially regulated by Wnt-5a and Wnt-1 in C57mg mouse mammary epithelial cells. BMC Developmental Biology. 2003;3:2.
   Google Scholar
• Li M, Bharadwaj U, Zhang R, et al. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Molecular Cancer Therapeutics. 2008;7:286–296.
   PubMed Web of Science ®Google Scholar
• Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. Cell. 1990;60:509–520.
   PubMed Web of Science ®Google Scholar
• Gessler M, Poustka A, Cavenee W, et al. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature. 1990;343:774.
   Web of Science ®Google Scholar
• Oji Y, Nakamori S, Fujikawa M, et al. Overexpression of the Wilms’ tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Sci. 2004;95:583–587.
   PubMed Web of Science ®Google Scholar
• Elisseeva OA, Oka Y, Tsuboi A, et al. Humoral immune responses against Wilms tumor gene WT1product in patients with hematopoietic malignancies. Blood. 2002;99:3272–3279.
   PubMed Web of Science ®Google Scholar
• Ambrosini G, Adida C. Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Medicine. 1997;3:917.
   Web of Science ®Google Scholar
• Engels K, Knauer S, Metzler D, et al. Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker. The Journal of Pathology. 2007;211:532–540.
   PubMed Web of Science ®Google Scholar
• Li F, Yang J, Ramnath N, et al. Nuclear or Cytoplasmic Expression of Survivin: What Is the Significance? International Journal of Cancer. 2005;114509–512.
   Google Scholar
• Virrey JJ, Guan S, Li W, et al. Increased survivin expression confers chemoresistance to tumor-associated endothelial cells. Am J Pathol. 2008;173:575–585.
   PubMed Web of Science ®Google Scholar
• Hirokawa N, Noda Y. Okada Y: kinesin and dynein superfamily proteins in organelle transport and cell division. Curr Opin Cell Biol. 1998;10:60–73.
   PubMed Web of Science ®Google Scholar
• Echard A, Jollivet F, Martinez O, et al. Interaction of a Golgi-associated kinesin-like protein with Rab6. Science (80- ). 1998;279:580–585.
   PubMed Web of Science ®Google Scholar
• Hill E, Clarke M. Barr FA: the Rab6‐binding kinesin, Rab6‐KIFL, is required for cytokinesis. The EMBO Journal. 2000;19:5711–5719.
   PubMed Web of Science ®Google Scholar
• Fontijn RD, Goud B, Echard A, et al. The human kinesin-like protein RB6K is under tight cell cycle control and is essential for cytokinesis. Mol Cell Biol. 2001;21:2944–2955.
   PubMed Web of Science ®Google Scholar
• Costache M, Ioana M, Iordache S, et al. VEGF expression in pancreatic cancer and other malignancies: a review of the literature. Romanian Journal of Internal Medicine. 2015;53:199–208.
   PubMed Web of Science ®Google Scholar
• Ziogas AC, Gavalas NG, Tsiatas M, et al. VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2. International Journal of Cancer. 2012;130:857–864.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Onishi H, Wada J, et al. VEGFR2 is selectively expressed by FOXP3high CD4+ Treg. Eur J Immunol. 2010;40:197–203.
   PubMed Web of Science ®Google Scholar
• Gjertsen MK, Bakka A, Breivik J, et al. Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study. International Journal of Cancer. 1996;65:450–453.
   PubMed Web of Science ®Google Scholar
• Wobser M, Keikavoussi P, Kunzmann V, et al. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunology, Immunotherapy. 2006;55:1294–1298.
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Lee KM, McKolanis J, et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunology, Immunotherapy. 2005;54:254–264.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Ueno T, Kawaoka T, et al. MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res. 2005;25:3575–3579.
   PubMed Web of Science ®Google Scholar
• Yanagimoto H, Shiomi H, Satoi S, et al. A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncology Reports. 2010;24:795–801.
   PubMed Web of Science ®Google Scholar
• Miyazawa M, Ohsawa R, Tsunoda T, et al. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci. 2010;101:433–439.
   PubMed Web of Science ®Google Scholar
• Yamaue H, Tsunoda T, Tani M, et al. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS‐PC Study. Cancer Sci. 2015;106:883–890.
   PubMed Web of Science ®Google Scholar
• Suzuki N, Hazama S, Ueno T, et al. A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer. Journal of Immunotherapy (Hagerstown, Md.. 1997;37:36:2014.
   Google Scholar
• Suzuki N, Hazama S, Iguchi H, et al. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS‐PC study. Cancer Sci. 2017;108:73–80.
   PubMed Web of Science ®Google Scholar
• Shindo Y, Hazama S, Suzuki N, et al. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. Journal of Experimental & Clinical Cancer Research. 2017;36:36.
   PubMed Web of Science ®Google Scholar
• Nishida S, Ishikawa T, Egawa S, et al. Combination gemcitabine and WT1 peptide vaccination improves progression-free survival in advanced pancreatic ductal adenocarcinoma: A phase II randomized study. Cancer Immunology Research:Canimm.. 2018;0386.2017;320-331.
   Google Scholar
• Middleton G, Silcocks P, Cox T, et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. The Lancet Oncology. 2014;15:829–840.
   PubMed Web of Science ®Google Scholar
• Koido S, Homma S, Okamoto M, et al. Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms’ Tumor 1 (WT1)–specific MHC Class I/II–restricted Epitopes for Pancreatic Cancer. Clinical Cancer Research. 2014;20:4228–4239.
   PubMed Web of Science ®Google Scholar
• Mayanagi S, Kitago M, Sakurai T, et al. Phase I pilot study of Wilms tumor gene 1 peptide‐pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer. Cancer Sci. 2015;106:397–406.
   PubMed Web of Science ®Google Scholar
• Hirooka Y, Kawashima H, Ohno E, et al. Comprehensive immunotherapy combined with intratumoral injection of zoledronate-pulsed dendritic cells, intravenous adoptive activated T lymphocyte and gemcitabine in unresectable locally advanced pancreatic carcinoma: a phase I/II trial. Oncotarget. 2018;9:2838-2847.
   Google Scholar
• Le DT, Wang-Gillam A, Picozzi V, et al. Safety and survival with GVAX pancreas prime and Listeria monocytogenes–expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. Journal of Clinical Oncology. 2015;33:1325-1333.
   Web of Science ®Google Scholar
• Kano Y, Iguchi T, Matsui H, et al. Combined adjuvants of poly (I: C) plus LAG‐3‐Ig improve antitumor effects of tumor‐specific T cells, preventing their exhaustion. Cancer Sci. 2016;107:398–406.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science (80- ). 2015;348:124–128.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet. 2016;387:1540–1550.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wolfgang CL. Zheng L: precision Immuno-Oncology: prospects of Individualized Immunotherapy for Pancreatic Cancer. Cancers. 2018;10:39.
   Web of Science ®Google Scholar
• Lutz E, Wu A, Bigelow E, et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res. 2014;2:616–631; PMID: 24942756, CIR-14-0027.
   PubMed Web of Science ®Google Scholar
• Jiang H, Hegde S, Knolhoff BL, et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nature Medicine. 2016;22:851-860.
   Web of Science ®Google Scholar
• Nywening TM, Wang-Gillam A, Sanford DE, et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. The Lancet Oncology. 2016;17:651–662.
   PubMed Web of Science ®Google Scholar
• Balachandran VP, Łuksza M, Zhao JN, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017;551:512-516.
   Web of Science ®Google Scholar
• Patel RK, Ko AH, Onners B, et al. A phase 2, multicenter study of FOLFIRINOX followed by ipilimumab in combination with allogeneic GM-CSF transfected pancreatic tumor vaccine in the treatment of metastatic pancreatic cancer. J Clin Oncol. 2014 32:TPS4160-TPS4160.
   Google Scholar
• Kakarla S. Gottschalk S: CAR T cells for solid tumors: armed and ready to go? Cancer journal (Sudbury, Mass.). 20:151 (2014).
   Google Scholar
• Adachi K, Kano Y, Tamada K, et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. In Nature biotechnology. 2018;346-351.
   Google Scholar